Rekombinanter CD4 (Ibalizumab Biosimilar) Antikörper
Kurzübersicht für Rekombinanter CD4 (Ibalizumab Biosimilar) Antikörper (ABIN7795119)
Target
Antikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Güteklasse
-
-
Expressionssystem
- Mammalian cells
-
Verwendungszweck
- Ibalizumab Biosimilar, Human CD4 Monoclonal Antibody
-
Produktmerkmale
- What is ibalizumab biosimilar research grade? Ibalizumab Biosimilar uses the same protein sequences as the therapeutic antibody ibalizumab which is a non-immunosuppressive humanised monoclonal antibody that binds CD4, the primary receptor for HIV, and inhibits HIV from entering cells. It is a post-attachment inhibitor, blocking HIV from binding to the CCR5 and CXCR4 co-receptors after HIV binds to the CD4 receptor on the surface of a CD4 cell. Post-attachment inhibitors are a subclass of HIV drugs called entry inhibitors.
-
Aufreinigung
- Protein A or G affinity column
-
Reinheit
- >95 % by reducing SDS-PAGE
-
Endotoxin-Niveau
- < 1 EU per 1 mg of the protein by the LAL method
-
Immunogen
- Human CD4
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- > 3 mg/mL
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- CD4 (Ibalizumab Biosimilar)
-
Andere Bezeichnung
- Ibalizumab Biosimilar
-
Substanzklasse
- Biosimilar
Target
-